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Snakebite envenomation is considered a highly relevant public health hazard in South
America, having an impact in terms of mortality and morbidity. In Brazil, Bothrops (sensu
latu) poisoning is responsible for 90% of the snakebites and in patients treated at the Vital
Brazil Hospital (Butantan Institute) this index reaches 97.5%. The objective of the present
study was to analyze more speciﬁcally the ability of the antibothropic antivenom,
produced by the Butantan Institute, São Paulo, Brazil, to neutralize metallo-and serine
peptidases, known as the major toxins present in Bothrops jararaca venom. A set of Fret
peptides (Free Ressonance Energy Transfer) was studied using the BjV (B. jararaca venom)
and site-directed inhibitors PMSF, EDTA and 1,10-phenanthroline. Two substrates were
reached to be used as speciﬁc tools for studies with metallo peptidases, Abz-FASSAQ-
EDDnp, and the serine peptidases, Abz-RPPGFSPFRQ-EDDnp. In disagreement with the
literature, the use of both substrates and the antibothropic serum showed a weak
neutralization of the serine peptidases present in this venom and a strong neutralization of
the metallo peptidases. In order to investigate possible mechanisms of action that have not
yet been described for the serine peptidases from the BjV, the present study shows for the
ﬁrst time a new tyrosine-speciﬁc chymotrypsin-like and angiotensin-degrading serine
peptidase activity, that was partially blocked by the antibothropic serum. In conclusion,
the antivenom presented a good neutralization of metallo peptidases but not of serine
peptidases, indicating that further studies about serine peptidases immunogenicity are
necessary to improve the antibothropic serum.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Snake venom poisoning is a public health issue for many
countries and despite the great difﬁculty in raising the
actual data of these accidents, some studies show that
there are about 5.4 million to 5.5 million accidents, more106.
.V. Portaro).
lsevier OA license.than 400,000 amputations and about 20,000 to 125,000
deaths per year worldwide. These numbers surpass several
other neglected tropical diseases in occurrence and
number of fatalities, such as leishmaniasis, dengue, schis-
tosomiasis, cholera, and Chagas disease (Williams et al.,
2010). In addition, snake bites only joined the list of
neglected tropical diseases recently, in April 2009, showing
that it was not seen as an important public health issue
until recently (World Health Organization, 2011).
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in the midst of several factors which complicate its solu-
tion, such as: proﬁle of the victim; lack of training programs
for health staff; underreporting of accidents; improvement
in the production, storage and distribution of sera; further
studies on quality and safety of serums produced (World
Health Organization, 2010).
The most recommended treatment in cases of snakebite
accidents is serum therapy. The neutralizing ability is
assessed by evaluating the capacity of the antivenom to
inhibit the lethal action of the reference venom, i.e., from
Bothrops jararaca, in a murine model (World Health
Organization, 1981). The antivenom produced by the
Butantan Institute is prepared by immunization of horses
with a mixture of venoms of the species: Bothrops alter-
natus (12.5%), Bothrops jararacussu (12.5%), Bothrops moo-
jeni (12.5%), Bothrops neuwiedi (12.5%) and B. jararaca (50%).
But in Brazil, there are several species of the Bothrops genus
(sensu latu) which differ widely in composition of venom
and with regard to the neutralization of its components,
such as metalloproteinase, PLA2 and hyaluronidases
(Queiroz et al., 2008). Indeed, the interspeciﬁc variation in
venom composition and toxicity of Brazilian snakes from
the Bothrops genus, poses a challenge to the provision of
antivenom to be used in accidents caused by any one of the
species. The antibothropic serum produced by the Butantan
Institute has saved many lives over the years, but it is
known that in the case of Bothrops poisoning, evenwith the
application of the serum in large quantities, it still does not
address the local symptoms of the bite, although it does
improve the systemic symptoms (Cardoso et al., 1993). The
Bothrops genus is widely distributed in the Neotropics,
occurring fromMexico to northern Argentina, being absent
only in Chile. The B. jararaca species occurs from the South
of Bahia to northern Argentina and Paraguay, being
distributed in Brazil in the states of Minas Gerais, Espírito
Santo, Rio de Janeiro, São Paulo, eastern Mato Grosso do
Sul, Paraná and Rio Grande do Sul (Gomes and Puorto,
1993). Bothrops poisoning is responsible for 90% of the
snakebites in Brazil (Ministério da Saúde, 2001) and in
patients treated at the Vital Brazil Hospital (Butantan
Institute), where the species were identiﬁed, this index
reaches 97.5% (Ribeiro and Jorge, 1997). Despite the great
variety of components present in the venom from the
Bothrops species, it is known that proteolytic enzymes of
serine and metalloproteinase classes are the most relevant
toxins in cases of human accidents. Also, results of pro-
teomic analysis performed with the venom of B. jararaca,
indicate that 51.5% and 14% of components are metallo- and
serine peptidases, respectively (Fox and Serrano, 2008).
Snake venom metallo peptidases, also known as SVMPs
(Snake Venom Metalloproteinases), act mainly as hemor-
rhagic factors, degrading proteins such as laminin, ﬁbro-
nectin, collagen type IV and proteoglycans from the
endothelial basal membrane (Fox and Serrano, 2005).
SVMPs can also module the release of cytokines (Laing and
Moura-da-Silva, 2005) and inhibit platelet aggregation
(Schattner et al., 2005). Taken together, these two effects,
associated with the proteolytic digestion of the basal
membrane, are considered to be the major mechanism of
SVMP-induced hemorrhage. On the other hand, SVSPs(Snake Venom Serine Proteases) are enzymes which affect
the hemostatic system. They act on a variety of components
of the coagulation cascade, on the ﬁbrinolytic and kalli-
krein–kinin systems and on cells to cause an imbalance of
the hemostatic system of the prey (Pirkle, 1998).
Taking into account that snake venom poisoning is
a public health issue and the major toxins present in the
venoms from the Bothrops species are SVMPs and SVSPs,
the main focus of this study was to verify the blocking
potential of the antibothropic serum produced by the
Butantan Institute, on the peptidase activities from both
classes (metallo peptidases and serine peptidases), using
both FRETs and natural biological peptides.
2. Materials and methods
2.1. Reagents
Ethylene diamine tetracetic acid (EDTA), phenyl-
methanesulfonylﬂuoride (PMSF), 1,10-phenantroline,
angiotensin I (ang I), dynorphin1-13 (dyn A), neurotensin1-
13 and bradykinin were purchased from Sigma–Aldrich,
acetonitrile from Carlo Erba and triﬂuoroacetic acid (TFA)
from J.T. Baker. FRETs peptides, Abz-FASSAQ-EDDnp (Abz-
Metal) and Abz-RPPGFSPFRQ –EDDnp (Abz-Serine), were
provided by Prof. Luiz Juliano Neto, from the Department of
Biophysics of UNIFESP-EPM. These peptides were synthe-
sized using automated solid-phase synthesis (Hirata et al.,
1994).
2.2. Venoms and antivenom
The venom of B. jararaca (50 mg), Bothrops moogeni
(1.0 mg), B. alternatus (1.0 mg), B. jararacussu (1.0 mg) and
B. neuwiedi (1.0 mg) were provided by the Herpetology
Laboratory from the Butantan Institute, São Paulo, Brazil.
The venom of B. jararacawas pooled from 2500 specimens
and lyophilized. The stock solutions were prepared in PBS
buffer, containing 50 mM phosphate and 20 mM NaCl, pH
7.4 at 1.0 mg/mL. The antibothropic serum produced by
the hyperimmunization of horses with a pool of venoms
from B. alternatus (12.5%), B. jararaca (50%), B. jararacussu
(12.5%), B. moojeni (12.5%) and B. neuwiedi (12.5%) was
obtained from the Hyperimmune Plasmas Processing
Section, Butantan Institute, São Paulo, Brazil. The anti-
venom used (batch no. 0506110) had a protein concen-
tration of 1.8 g/dL and each milliliter was able to
neutralize 6.61 mg of B. jararaca venom (lethality test in
mice).
2.3. Determination of protein concentration
This assay was executed according to Smith (1985),
using a “BCA Protein Assay” Kit (Pierce Biotechnology, EUA)
and serum albumin (BSA – Calbiochem, EUA) as reference
in an Elisa reader (Multiskan EX, Labsystems, Finland).
2.4. Enzymatic assays
The peptidase activity assay was conducted in a 7.4 pH
PBS buffer (ﬁnal volume 100 mL) containing 50 mM
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plates, and the peptide substrates in a ﬁnal concentration
of 5 mM. The reactions occurred at 37 C and were initiated
by the addition of 1 mL of BjV (2.74 mg/mL with Abz-Metal
and 0.18 mg/mL with Abz-Serine). The reactions were
monitored (ﬂuorescence at lEM 420 nm and lEx 320 nm) in
a ﬂuorescence spectrophotometer (Victor 3 Perkin–
Elmer, Boston, MA, USA), as described by Araujo et al.
(2000). Speciﬁc peptidase activity was expressed as
units of free ﬂuorescence of cleaved substrate per
minute per mg of venom. There was an incubation period
of 30 min at room temperature when phenyl-
methanesulfonylﬂuoride (1 mM, PMSF) and 1,10-
phenantroline (5 mM) where tested. The EDTA
(100 mM) was used without pre-incubation time. When
necessary, control samples were made in the presence of
the same volume of ethanol used in the preparation of
inhibitors stock solutions (PMSF and 1,10-phenantroline).
The experiments were made in triplicate.
2.5. HPLC analysis of peptides hydrolyzed by Bothrops spp
venoms
The peptide solutions of angiotensin I (65 mM),
dynorphin1-13 (31 mM) neurotensin 1-13 (12 mM) and
bradykinin (50 mM) were incubated in 7.4 pH PBS buffer
(50 mM phosphate and 20 mM NaCl) with 2.0, 2.5, 5.0 and
3 mL of BjV (2.74 mg/mL) for each substrate, respectively, at
37 C for 1–4 h, with a pre-incubation period of 30 min at
room temperaturewhen testedwith EDTA (100mM), PMSF
(1mM) and 1,10-phenantroline (5 mM). Hydrolysis products
were separated by reverse-phase HPLC (Prominence, Shi-
madzu), collected manually, and submitted to mass spec-
trometry analysis. The HPLC conditions used for the
analytical procedure were 0.1% triﬂuoroacetic acid (TFA) in
water (solvent A), and acetonitrile and solvent A (9:1) as
solvent B. The separations were performed at a ﬂow rate of
1 mL/min using a Shim-pack VP-ODS C-18 column
(4.6  150 mm) and a 20–60% gradient of solvent B over
20 min. In all cases, elution was followed by ultraviolet
absorption (214 nm). The scissile bonds in the peptides
were determined by mass spectrometry analyses. The
peptide fragments were detected by scanning fromm/z 100
to m/z 1300 using an Esquire 3000 Plus Ion trap Mass
Spectrometer with ESI and esquire CONTROL software
(Bruker Daltonics, MA, USA). Puriﬁed 18O-labeled or
unlabeled oxidized W derivatives were dissolved in
a mixture of 0.01% formic acid:acetonitrile (1:1) and
infused into the mass (direct infusion pump) spectrometer
at a ﬂow rate of 240 mL/h. The skimmer voltage of the
capillary was 40 kV, the dry gas was kept at 5.0 L/min, and
the source temperature was maintained at 300 C.
After deﬁning the natural peptides that were hydro-
lyzed by BjV, the ability of the other venoms to hydrolyze
angiotensin I (65 mM) was analyzed using 4 mL of each one
(B. alternatus [5.74 mg/mL], B. jararacussu [3.11 mg/mL], B.
moojeni [0.86 mg/mL] and B. neuwiedi [0.11 mg/mL]). The
scissile bonds found in angiotensin-I produced by these
venoms were deduced by internal standardization of the
HPLC system, using the results obtained with B. jararaca as
reference.2.6. Antibothropic serum neutralization of the venoms
2.6.1. Fluorimetric assays
The ability of the antibothropic serum to neutralize the
venoms proteolytic activities was estimated by incubating it
with Bothrops spp. venoms. Samples of Bothrops venoms
were incubated, at room temperature, in the presence and
absence of the antibothropic serum. The residual proteolytic
activities of the venoms were measured as described above,
usingbothFRETs substrates. Thevolumeof theantibothropic
serum and the pre-incubation time for serumneutralization
of the proteolytic activities were established by using the B.
jararaca venom. After establishing the best conditions to
neutralize the metallo- and serine peptidases from the B.
jararaca venom, the other Bothops spp venoms were tested
(B. alternatus, B. jararacussu, B. moojeni and B. neuwiedi). The
venomswere used in volumes of 2.0 mL when the Abz-Metal
was utilized as substrate and 0.2 mL for the kinetics with the
Abz-Serine (see concentration on 2.5). For the maximum
blocking effect of the proteolytic activity, the venoms were
incubated with 10 mL of the antibothropic serum for 30 min
at room temperature. After this period, 5 mM of each
substrate was added and the residual activity wasmeasured
asdescribedabove. Theexperimentsweremade in triplicate.
2.6.2. HPLC assays
The same concentrations of Bothrops spp venoms
described in the angiotensin-I degrading assays were
utilized to determine the neutralizing potential of the
commercial serum. Thus, after a pre-incubation time
(venoms and antivenom), 65 mMof angiotensin I was added
and after 1 hmore samples were analyzed by HPLC reverse-
phase.
3. Results
3.1. Search for speciﬁc substrates for the different classes of
proteases
The ﬁrst step in this study was to ﬁnd ways to differ-
entiate the major classes of proteolytic enzymes present in
the B. jararaca venom, the serine peptidases and the met-
allo peptidases. For this, a set of FRETs substrates was tested
and two substrates that are mostly hydrolyzed by each one
of these classes were found. The metallo peptidases act
mainly on Abz-FASSAQ-EDDnp and the serineproteases on
Abz-RPPGFSPFRQ-EDDnp. Table 1 shows that Abz-FASSAQ-
EDDnp hydrolysis was totally inhibited by both EDTA and
1,10-phenantroline and, thus, it was named here as Abz-
Metal. This was unlike the hydrolysis of Abz-
RPPGFSPFRQ-EDDnp peptide, that was strongly inhibited
by PMSF (71%), and was thus named as Abz-Serine. It is
important to mention that the rate of hydrolysis of Abz-
Metal by the BjV is around 18 times lower when
compared to that of Abz-Serine (Table 1).
The preference of both protease classes for these
substrates was also found in venoms from other species of
the Bothrops genus that comprise the pool used in the
production of the antivenom (Fig. 1), with exception of the
Abz-Serine hydrolysis by the B. neuwiedi venomwhich was
inhibited by PMSF with lower potency.
Table 1
Inhibition of hydrolysis of the Abz-Metal and Abz-Serine by BjV using
classical inhibitors of metallopeptidase (EDTA and 1.10-phenantroline)
and serinepeptidase (PMSF).
Speciﬁc activity (UF/min/ìg)a
Abz-Metal Abz-Serine
Control 544.7 9716.16
EDTA n.h.b 9428.72
1.10-Phenantroline n.h. 6179.48
PMSF 390.4 2791.78
Assays were carried out in 100 mL of 50 mM phosphate buffer, pH 7.4,
containing 20 mM NaCl, at 37 C, using 5 mM of Abz-peptides and 2.74 mg
and 0.18 mg of BjV (for Abz-Metal and Abz-Serine, respectively). The SD of
kinetic results in each case was never greater than 5% of the value ob-
tained. The results were a mean of three independent experiments.
a UF ¼ Units of ﬂuorescence.
b n.h. no hydrolysis detected.
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The tests were conducted using the maximum dose of
BjV neutralization that was found (10 ìL of antibothropic
serum), and incubated at room temperature for 30 min
using the Abz-peptides. When the venom from B. jararaca
was used, we observed a great neutralization of proteolytic
activity of metallo peptidases that act on the substrate Abz-
Metal, reaching levels above 90%, and a poor inhibition of
serine peptidases that act on Abz-Serine, with levels belowFig. 1. Hydrolysis of FRETs substrates and the effect of classical inhibitors to
serinepeptidases and metallopeptidases. Inhibition effect of PMSF, EDTA and
1,10-phenantroline upon the hydrolysis of Abz-Serine (Panel A) and Abz-
Metal (Panel B), by venoms from B. jararacussu, B. neuwiedi, B. alternatus
and B. moojeni. The experiments were made in triplicate. The SD of kinetic
results in each case was never greater than 5% of the value obtained.40% (Table 2). After determining the best condition to
neutralize the proteolytic activity of BjV, the same protocol
was used to verify the blocking effect of the commercial
serum upon the other venoms used to compose the
immunization pool: B. alternatus, B. jararacussu, B. moojeni
and B. neuwiedi. Fig. 2 shows that the other Bothrops spp
venoms studied here present the same pattern of activities
that were observed when the B. jararaca venom was used.
The hydrolysis of Abz-Serine by the B. neuwiedi venomwas
not inhibited through the use of the antivenom. The results
obtained using B. jararaca and B. moojeni venoms showed
inhibition levels of Abz-Serine hydrolysis of around 35%.
The hydrolysis of Abz-Metal by the B. alternatus venomwas
blocked around 70% by the commercial serum. For the
other species, the results obtained using the Abz-Metal as
substrate always reached levels above 90%. Thus, the use of
Abz-Metal and the antivenom reaching nearly 100% of
inhibition in return got poor inhibition of serine peptidases
that act on Abz-Serine with levels below 50%–0% inhibition
(Fig. 2).3.3. HPLC analysis of natural peptides hydrolyzed by BjV
One of our goals was to ﬁnd new peptidic substrates
that could be hydrolyzed by bothropic venoms and that
could explain in greater depth the Bothrops venoms
mechanism. For this, four human biologically active
peptides, possibly related to any physiological change on
the victim, were tested. Table 3 shows the rate of hydro-
lyzes of angiotensin I, dynorphin1-13, neurotensin1-13
and bradykinin, by the B. jararaca venom. In this set of
putative substrates, only bradykinin was not hydrolyzed by
the BjV and a good cleavage of angiotensin I was observed.
Dynorphin1-13 was also well hydrolyzed by the B. jararaca
crude venom, followed by the neurotensin1-13 degrada-
tion. Table 3 also shows the cleavage points determined in
angiotensin I and dynorphin1-13. As can be observed,
angiotensin I presents one cleavage point between the
residues Tyr–Ile, that was totally blocked by PMSF and not
affected by EDTA or 1,10-phenantroline. Moreover, the
commercial serum produced by the Butantan Institute was
able to reduce only 44% of the hydrolysis of angiotensin I
by BjV.
Dynorphin1-13 presents two scissile bonds, between
the residues Arg–Arg and Lys–Leu, that were principally
blocked by PMSF (88%) and partially blocked by EDTATable 2
Serum neutralization effect upon the proteolytic activity of Bothrops jar-
araca venom using Abz-Metal and Abz-Serine as substrates.
Speciﬁc activity (UF/min/mg) Inhibition (%)
Substrate Control Serum
Abz-Metal 333.3 22.3 93.3
Abz-Serine 8362.81 5335.5 36.2
Assays were carried out in 100 mL of 50 mM phosphate buffer, pH 7.4,
containing 20 mM NaCl, at 37 C, using 5 mM of Abz-peptides and 2.74 mg
and 0.18 mg of BjV (for Abz-Metal and Abz-Serine, respectively). The SD of
kinetic results in each case was never greater than 5% of the value ob-
tained. The volume of serumwas 10 mL with a pre-incubation of 30 min at
room temperature.
Fig. 2. Inhibition of serinepeptidases and metallopeptidases present in
Bothrops spp venoms. Blocked effect of the antibothropic serum on hydro-
lysis of Abz-Serine and Abz-Metal by venoms from B. jararaca, B. jararacussu,
B. neuwiedi, B. alternatus and B. moojeni. The experiments were made in
triplicate. The SD of kinetic results in each case was never greater than 5% of
the value obtained.
Table 4
Blocked effect of the antibothropic serum on hydrolysis of angiotensin I by
the venoms of B. jararaca, B. alternatus, B. moojeni, B. neuwiedi and B.
jararacussu.
Venom Speciﬁc activity (mM/min/mg) Inhibition (%)
Control Serum
B. jararaca 0.18 0.10 44
B. alternatus 0.046 0.028 61
B. moojeni 0.15 0 100
B. neuwiedi 1.66 0.075 96
B. jararacussu 0.046 0.01 21
Assays were carried out in 500 mL of 50 mM phosphate buffer, pH 7.4,
containing 20mMNaCl, at 37 C, using 65 mMof angiotensin I. The venoms
were used in different concentrations (see materials and methods for
details). The SD of kinetic results in each case was never greater than 5% of
the value obtained. The volume of serum was 10 mL with a pre-incubation
of 30 min at room temperature.
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antibothropic serumwas able to block 48% of the hydrolytic
activity of the venom on dynorphin A cleavage.
Since the observation of angiotensin I cleavage is mainly
due by serine peptidases and partially blocked by the
antivenom, we decided to test the other four bothropic
venoms used to make the immunization pool.
The results obtained with the venoms used to compose
the immunization pool, again showed the presence of
a chymotrypsin-like activity in these venoms, althoughwith
distinct speciﬁc activities (Table 4). The cleavage points
were unique between Tyr–Ile bonds (data not shown) and
were determined by the internal standardization of the
HPLC conditions using the BjV. The blocked effect of the
antibothropic serumwas different for each venom, showing
variations in their composition. The angiotensin-I hydro-
lyzes by the venom from B. jararacussu and B. jararacawere
only partially blocked by the commercial antivenom
(Table 4). In contrast, angiotensin I degradation was fully
inhibited by using the antivenom when the venoms from
B. moojeni and B. neuwiedi were used.Table 3
Hydrolysis of bioactive peptides by B. jararaca venom.
Speciﬁc activity (mM/min/mg) Cleavage site
Control EDTA PMSF 1.10-Phe Serum
Angiotensin I 0.18 0.23 n.h.a 0.21 0.10 DRVY///IHPFHL
Dyn 1-13 0.058 0.04 0.007 0.054 0.03 YGGFLR//
RIRPK//LK
Neurotensin 0.0012 n.d.b n.d. n.d. n.d. n.d.
Bradykinin n.h. – – – – –
The peptide solutions (12–65 mM) were incubated in 7.4 pH PBS buffer
containing 50mMphosphate and 20mMNaCl with BjV, at 37 C for 1–4 h,
with a pre-incubation period of 30 min at room temperature when tested
with EDTA, PMSF and 1.10-phenantroline. The volume of serumwas 10 mL
with a pre-incubation of 30 min at room temperature. The SD of kinetic
results in each case was never greater than 5% of the value obtained. The
experiments were made in triplicate.
a n.h. – no hydrolysis detected.
b n.d. – not determined.4. Discussion
Although it was proposed that B. jararaca and Bothrops
neuwied should be included in the genus Bothropoides, and
B. alternatus into genus Rhinocerophis, there is no clear
consensus about the systematics of this group (SBH, 2007).
Since human envenomations involving these species are
treated with the antibothropic serum, this study still
considers these snake venoms as belonging to the genus
Bothrops.
The objective of the present study was to analyze the
ability of the antivenom produced by the Butantan Insti-
tute, São Paulo, Brazil, to neutralize B. jararacamajor venom
toxins. A set of FRET peptides (Free Ressonance Energy
Transfer) was studied using the BjV and site-directed
inhibitors PMSF, EDTA and 1,10-phenanthroline. The
results indicated that two substrates can be used as speciﬁc
tools for studies with metallo peptidase, Abz-Metal (Abz-
FASSAQ-EDDnp), and serine peptidases, Abz-Serine (Abz-
RPPGFSPFRQ-EDDnp). The use of both substrates and the
antivenom produced by the Butantan Institute showed
a weak neutralization of serine peptidases in this venom
and a strong neutralization of themetallo peptidases. These
results are in disagreement with the literature, since the
symptoms attributed to the serine peptidases are consid-
ered to be controlled when the antibothropic serum is
administered (Cardoso et al., 1993).
Indeed, the antivenom is capable of reducing the
systemic effects caused by poisoning from Bothrops snakes,
but it is not effective to block the local effects observed in
accidents with humans (Cardoso et al., 1993). This obser-
vation leads us to believe that some of the enzymes present
in the snake venom are not neutralized by the antivenom -
i.e.: that serine peptidases may be related to local effects
through the activation of latent forms of human MMP’s
(Saravia-Otten et al., 2004).
The serine peptidases of snake venoms are classiﬁed in
clan SA of S1 of the chymotrypsin family (Rawlings et al.,
2010). The mammalian trypsin and enzymes present in
poisons have similar “fold” and are believed to have
evolved from a common ancestor (Itoh et al., 1988). The B.
jararaca venom contains several serineproteases, and the
best characterized are: Bothrops protease A (BPA), recently
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able to release bradykinin from low molecular weight
bovine kininogen; TL-BJ, a thrombin-like protease with
clotting activity; PA-BJ, an enzyme with activity in aggre-
gating platelet-rich plasma and suspensions of washed
platelets; Bothrombin is a serine peptidase which acts by
cleavage of ﬁbrinopeptide A without affecting ﬁbrinopep-
tide B (see Serrano and Maroun as review).
Although the SVSP described above have deﬁned
protein substrates, there are no published data indicating
possible biologically active peptides as substrates for these
enzymes. In fact, the majority of the methods used to
screen the proteolytic activities of animal venoms have not
considered the possibility of peptidase activities, which
could contribute directly or indirectly to the envenomation.
Peptidase activity can increase permeability to the venom
toxin targets, and produces other peptides with different
activities from the parent peptide and destruction of both
epitopes MHC class I and II.
The results presented here show that the crude venom
of B. jararacawas able to cleave angiotensin I, dynorphin1-
13 and, to a lesser extent hydrolysis neurotensin1-13.
Surprisingly, angiotensin I was well hydrolyzed by the
BjV, and the use of 1,10-phenantroline and PMSF clearly
indicated that it is a serine protease-like activity. The use of
the antibothropic serum showed, again, a ﬂaw in the action
of the commercial antivenom to block serine peptidases.
The cleavage point in ang I was determined as Tyr–Ile by
mass spectrometric analysis and was the same hydrolysis
observed using the venoms from B. jararacussu, B. neuwiedi,
B. alternatus and B. moojeni. These results are in accordance
with other serine peptidases activities reported as being
able to hydrolyze ang I between the Y–I bond, like human
kallikrein 1-related peptidase 3 (KLK3), best known as
‘‘prostate-speciﬁc antigen” (PSA) (Andrade et al., 2010) and
rat chymase-1 (Sanker et al., 1997). Recently, a serine
protease puriﬁed from the venom of Vipera libetina showed
the same angiotensin I scissile bond reported here (Siigur
et al., 2010).
The decapeptide ang I (DRVYIHPFHL) is a precursor of
the ang II (DRVYIHPF), well-known as an important
hypertensive peptide. The most important peptidase
responsible for the conversion of ang I to ang II is the
Angiotensin Converting Enzyme (ACE, peptidyl dipeptidase
A, EC 3.4.15.1) (Skeggs et al., 1956).Fig. 3. Primary sequence comparison: VLCTLP (Vipera lebetina chymotrypsin-like p
underlined, and asterisks (*) indicate identical amino acid residues. The symbols (:In this scenario, it is important to note that a family of
peptides with ACE inhibitory activity, the BPPs (Bradykinin-
Potentiating Peptides), is present in the venom of B. jar-
araca (Ferreira and Rocha e Silva, 1965; Ferreira et al., 1970;
Ondetti et al., 1971). One of then, the BPP-5a, is a molecule
that originally inspired the design of current commercial
inhibitors of ACE (Ondetti et al., 1977). Since the hypoten-
sive effects observed in accidents with humans are related
to the presence of BPPs, the destruction of angiotensin I is
another activity in this BjV that leads to in vivo hypotension.
Moreover, BjV contains a serine peptidase able to release
bradykinin from the low molecular weight kininogen (KN-
BJ) (Serrano et al., 1998). Apart from the results of angio-
tensin I hydrolysis, we also show that the bradykinin was
totally stable to the action of B. jararaca venom and no
cleavage could be detected even after a long period of
incubation. Taken together, it seems that the venom of B.
jararaca can be considered an arsenal that leads the victim
to hypotensive shock. Most critically, it is possible that
these activities, caused by BPPs and serine peptidases, are
not blocked by the antibothropic serum. It is important to
mention that the antibothropic serum produced by the
Butantan Institute presents high speciﬁc activity to
neutralize the lethal activity of the Bothrops venoms, when
compared with other commercial antivenoms (Dias da
Silva and Tambourgi, 2011).
Taking into account the hydrolyzes on the Tyr–Leu bond
in angiotensin I, it is possible to hypothesize that serine
proteinase BPA (Bothrops Protease A) could be responsible
for this activity, since it is able to cleave the insulin â chain
with a Tyr residue in the P1 position (Tyr26-Thr27;
Mandelbaum et al., 1967). Besides the same speciﬁcity to
substrate hydrolyzes, it is important to note a high degree
of similarity and identity between the serineproteases
amino acid sequences. The least degree of similarity can be
observed between KN-Bj  PA-Bj (63.4%) and the most
degree of similarity was found between BPA  PA-Bj
(71.6%). A recent report showing a serine protease from
Vipera lebetina venom, capable to cleave angiotensin I, also
shows a high degree of similarity (85%) and identity (75%)
with BPA, including in the catalytic residues (Fig. 3).
Dynorphin1-13 (dyn A, YGGFLRRIRPKLK) was also
hydrolyzed by the crude venom of B. jararaca, showing at
least two cleavage points (YGGFLR-RIRPK-LK), since the
fragment RIRPK was detected by mass spectrometryrotease) and BPA (Bothrops protease A). The catalytic triads are in bold and
) and (.) represent conserved and non conserved substitutions, respectively.
A.K. Kuniyoshi et al. / Toxicon 59 (2012) 124–131130analyses. Unlike angiotensin I, dyn A is hydrolyzed by both
classes of proteases, metallo- and serine peptidases, so this
activity was partially blocked by the commercial anti-
bothropic serum. The pathophysiological mean of dyn A
hydrolyzes is possibly correlated with pain sensation and
inﬂammation (Parik et al., 2010; Luo et al., 2008).
Many factors, including phylogeny, sex, geographic
origin, season, age and prey preference, may inﬂuence
composition of the venoms (Chippaux et al., 1991;
Mackessy et al., 2003; Furtado et al., 2006). In addition to
these considerations, the genus Bothrops shows the great-
est diversity when it comes to number of species,
morphology and natural history characteristics (Campbell
and Lamar, 2004). Given these characteristics, the devel-
opment of a polyvalent antivenom against accidents
involving this genus is an even greater challenge. Thus, the
production of better antivenoms should take into consid-
eration the quality of poisons, and what poisons should be
used to compose the pool of immunization. Finally, the
preclinical efﬁcacy of the antivenom must be carefully
evaluated. The inter specimen venom composition may be
evidenced by the different levels of chymotrypsin-like
activity and by the different potential blockers obtained
with the antibothropic serum and the ﬁve different
Bothrops venoms studied in this paper. These venom
composition variations may be an important factor to
explain the failure of the antibothropic serum and, addi-
tionally, three other factors also may be responsible for the
overall presented result. The ﬁrst factor suggests a lack of
immunoglobulins acting against serine peptidases present
in some venoms and the second factor may be related to
the failure of blocking by the antibodies, although theymay
be present. The third and important factor may be related
to degradation of the serine peptidases by the metallo
peptidases before the inoculation of horses with the pool of
venoms used for the production of antivenom, and this
degradation could destroy the epitopes responsible for the
production of immunoglobulins. These hypotheses are
under investigation in our laboratories through new
experiments, with the objective of developing strategies to
obtain a more effective antibothropic serum.
The antibothropic serum produced by the Butantan
Institute is one of the best in Latin America to reduce
mortality by snake poisoning from this genus. However,
this study showed a ﬂaw in the action of antibothropic
serum to neutralized serine peptidases and, to our knowl-
edge, this is the ﬁrst report on chymotrypsin-like activity in
the venom of B. jararaca.Acknowledgments
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